Track market-moving stories before they get noisy

Posted by Defense World Staff on Jul 25th, 2026

Bank of Nova Scotia cut its stake in Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) by 7.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,310,387 shares of the company’s stock after selling 112,613 shares during the quarter. Bank of Nova Scotia owned approximately 0.18% of Roivant Sciences worth $36,298,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ROIV. SBI Securities Co. Ltd. lifted its holdings in Roivant Sciences by 1,740.3% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after purchasing an additional 1,166 shares in the last quarter. Allworth Financial LP raised its position in shares of Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after buying an additional 583 shares during the period. Parallel Advisors LLC lifted its stake in shares of Roivant Sciences by 33.7% in the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock valued at $57,000 after purchasing an additional 520 shares during the last quarter. Kestra Advisory Services LLC acquired a new position in Roivant Sciences in the fourth quarter valued at about $47,000. Finally, Bessemer Group Inc. boosted its position in shares of Roivant Sciences by 21.8% during the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock worth $69,000 after purchasing an additional 441 shares during the period. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Roivant Sciences In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $33.16, for a total value of $6,632,000.00. Following the transaction, the chief executive officer directly owned 1,613,063 shares in the company, valued at approximately $53,489,169.08. This represents a 11.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Melissa B. Epperly sold 17,750 shares of Roivant Sciences stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $34.38, for a total transaction of $610,245.00. Following the sale, the director owned 16,474 shares of the company’s stock, valued at approximately $566,376.12. This trade represents a 51.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 1,855,913 shares of company stock worth $62,649,633. Corporate insiders own 10.80% of the company’s stock.

Analyst Ratings Changes Several research firms have weighed in on ROIV. HC Wainwright reaffirmed a “buy” rating and issued a $34.00 target price on shares of Roivant Sciences in a research report on Thursday, May 21st. Citigroup boosted their price target on shares of Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. Piper Sandler reissued an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Leerink Partners set a $42.00 price target on Roivant Sciences in a research note on Thursday, May 21st. Finally, Weiss Ratings lowered Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.59.

Read Our Latest Report on ROIV

Roivant Sciences Stock Down 0.3% Shares of NASDAQ:ROIV opened at $35.01 on Friday. The company has a market capitalization of $25.18 billion, a P/E ratio of -58.35 and a beta of 1.11. Roivant Sciences Ltd. has a 52-week low of $10.90 and a 52-week high of $37.00. The stock’s fifty day simple moving average is $32.24 and its 200-day simple moving average is $28.62.

Roivant Sciences Profile (Free Report)

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.

Featured Articles Five stocks we like better than Roivant Sciences AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Plugging In: How Kinder Morgan Powers Up Profits

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBank of Nova Scotia Sells 171,071 Shares of T-Mobile US, Inc. $TMUS

NEXT HEADLINE »Qualcomm Incorporated $QCOM Shares Sold by Bank of Nova Scotia

BASEL, Switzerland and LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026, to report its financial results for the first quarter ended June 30, 2026, and provide a business update.

April 02, 2026 05:00 ET  | Source: Roivant Sciences

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, highlighting a critical unmet therapeutic needLPP marks the fourth indication in brepocitinib’s expanding late-stage development programMultiple lines of evidence, including strong mechanistic rationale and clinically meaningful results in an investigator-initiated placebo-controlled study of brepocitinib in LPP, support rapid development of brepocitinib in this indicationA seamless Phase 2b/3 potentially registrational trial of brepocitinib in LPP enrolled its first subjects in March 2026Immunovant’s Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated greater levels of proptosis improvement from baseline after the initial 12-week high-dose period than after the following 12-week low-dose period, supporting the benefit of deeper IgG suppression. The hyperthyroid patients in the TED studies showed similar response rates of thyroid hormone normalization to those seen in the batoclimab Phase 2 study in Graves’ diseaseImmunovant remains focused on rapid advancement of IMVT-1402 in multiple indicationsRoivant will host an investor call to discuss these updates today, April 2, 2026, at 8:00 a.m. ET BASEL, Switzerland and LONDON and NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced a new Phase 2b/3 clinical program for brepocitinib in lichen planopilaris (LPP), a highly morbid inflammatory scalp disorder affecting approximately 100,000 adults in the United States, and reported the topline results from Immunovant’s two Phase 3 (GO) clinical studies evaluating batoclimab as an investigational treatment for adults with active, moderate-to-severe thyroid eye disease (TED).

Brepocitinib in LPP

LPP inflammation targets the stem cell-rich bulge region of the hair follicle (the permanent portion responsible for hair growth), resulting in generally irreversible hair loss and permanent scarring. LPP is also associated with other burdensome symptoms, including pain, burning, itching, and scaling and an increased risk of comorbidities such as other autoimmune diseases and skin cancers. There are currently no FDA-approved therapies to treat LPP.

“Lichen planopilaris (LPP) is what my colleagues and I refer to as a ‘trichologic emergency,’” said Dr. Kristen Lo Sicco, Chief of the Skin and Cancer Unit at NYU Langone Health, Board Member of the Scarring Alopecia Foundation, and Associate Professor of Dermatology at the Ronald O. Perelman Department of Dermatology at NYU Grossman School of Medicine. “Absent early diagnosis and aggressive intervention, patients experience rapid hair loss that is generally irreversible, leaves permanent scarring, and is often accompanied by erythema, scaling, pain, itching and burning sensations. Untreated LPP also leads to increased risk of skin cancers and other comorbidities. Efficacious FDA-approved treatments are urgently needed.”

Priovant recently began enrolling subjects in a seamless Phase 2b/3 study of brepocitinib in LPP, with the first subjects enrolled in March 2026. This program marks Priovant’s fourth indication in late-stage clinical development, alongside dermatomyositis (DM), non-infectious uveitis (NIU) and cutaneous sarcoidosis (CS). The U.S. Food and Drug Administration (FDA) recently granted Priority Review to brepocitinib’s New Drug Application (NDA) for DM and assigned a Prescription Drug User Fee Act (PDUFA) target action date in the third quarter of calendar year 2026. Topline Phase 3 data in NIU and Phase 3 study initiation in CS are expected in the second half of calendar year 2026.

“Expanding brepocitinib into lichen planopilaris continues our strategy of developing brepocitinib in highly morbid orphan conditions with limited treatment options and distinctive mechanistic benefits of dual JAK1/TYK2 inhibition,” said Ben Zimmer, Priovant CEO. “Moreover, as we look ahead to our expected product launch in DM in September, we see LPP as a strategic fit into a multi-indication rheum-derm rare disease franchise anchored by DM, with overlapping prescriber bases and thought leaders.”

Immunovant Phase 3 Studies in TED

Based on the pre-specified statistical analysis plan, the studies failed to meet their primary endpoint of ≥2mm proptosis responder rate at Week 24, following 12 weeks of high-dose and 12 weeks of low-dose batoclimab treatment. Safety results were consistent with previous findings, and no new safety signals were identified.

Patients in the TED studies had greater levels of proptosis improvement from baseline after the initial 12-week high-dose period than after the following 12-week low-dose period, supporting the benefit of deeper IgG suppression.

The subset of hyperthyroid patients in the TED studies showed similar response rates of thyroid hormone normalization to those seen in the batoclimab Phase 2 study in Graves’ disease.

Immunovant remains focused on rapidly advancing the clinical development of IMVT-1402, an investigational FcRn blocker, across multiple autoimmune diseases with significant unmet need, with Graves’ disease as a key strategic priority. Recent Phase 2 proof-of-concept data highlighted FcRn blockade as a potentially disease-modifying approach in Graves’ disease. Topline data from the potentially registrational studies of IMVT-1402 in Graves’ disease are expected in calendar year 2027.

Immunovant intends to review future plans for the development of batoclimab with its partner HanAll Biopharma Co., Ltd. (HanAll) and to provide an update on the program, in conjunction with HanAll, at a future date.

Investor Conference Call Information

Roivant will host a live conference call and webcast at 8:00 a.m. ET on Thursday, April 2, 2026, to discuss these updates.

To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website after the conference call.

About Roivant

Roivant (Nasdaq: ROIV) is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes brepocitinib, a potent small molecule inhibitor of JAK1 and TYK2 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, visit https://roivant.com.

Roivant Forward-Looking Statements

This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.

Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product candidates, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our product candidates following applicable regulatory approvals. In addition, any statements that refer to projections, forecasts or other characterizations of future events, results or circumstances, including any underlying assumptions, are forward-looking statements. Actual results may differ materially from those contemplated in these statements due to a variety of risks, uncertainties and other factors.

Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Investors

Keyur Parekh

[email protected]

Media

Stephanie Lee

[email protected]

Roivant Sciences (NASDAQ:ROIV) outlined plans to expand development of its JAK1/TYK2 inhibitor brepocitinib into lichen planopilaris (LPP) and provided an update on a Phase III thyroid eye disease (TED) trial for batoclimab during a conference call hosted by the company.

Brepocitinib expands into lichen planopilaris Roivant CEO Matt Gline said the company is moving “with urgency” to broaden brepocitinib across multiple indications, focusing on orphan immunology diseases with high unmet need, aligned biology for dual JAK1/TYK2 inhibition, and limited or no approved options. Alongside existing programs in dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis, Gline announced LPP as a new addition, describing it as “a fourth leg to the stool.”

Gline characterized LPP as a “severe and deeply unpleasant disease,” describing it as a highly morbid inflammatory scalp disorder that targets the permanent portion of the hair follicle, leading to generally irreversible hair loss and scarring that “can be permanently disfiguring.” He also cited intense symptoms including pain, itch, burning, redness, and scaling. He said there are no FDA-approved therapies and that patients often require chronic, aggressive, multimodal treatment that is frequently poorly effective.

Management noted the company views LPP as an “orphan-sized” opportunity, with Gline estimating “probably up to 100,000 U.S. patients,” and said the literature suggests prevalence and diagnosis are increasing over time.

Priovant details disease burden and biological rationale Ben Zimmer, CEO of Priovant, said LPP carries substantial burden beyond scalp symptoms, citing an association with increased risk of severe comorbidities, “including both skin cancer and other autoimmune diseases.” He added that clinicians often attempt multiple off-label therapies but that outcomes are limited and discontinuations are common due to tolerability and efficacy.

Zimmer said Priovant believes brepocitinib is well matched to LPP biology, describing the condition as driven primarily by “Th1 polarized T cell aberrant behavior.” He noted that interferon gamma and IL-12 are critical Th1 cytokines and that a JAK1/TYK2 inhibitor can suppress signaling of both. Zimmer pointed to experience in cutaneous sarcoidosis—another Th1-driven condition studied with brepocitinib—as supportive of the mechanistic fit.

Zimmer also referenced case reports and investigator-initiated studies of JAK1 and TYK2 inhibitors as clinical validation for the mechanism. He discussed a small, placebo-controlled investigator-initiated trial at Mount Sinai that used the LPPAI endpoint, which he described as “a generally noisy instrument” that is not preferred by clinicians. While urging caution about overinterpreting a small dataset, Zimmer said the broader takeaway supported proof-of-concept and helped underpin the company’s decision to move quickly.

Zimmer emphasized biomarker findings from that study, saying the “most powerful” aspect was evidence of brepocitinib activity on multiple markers of Th1-driven inflammation, including interferon gamma, IL-12, and chemokines such as CCL5.

Combined Phase IIb/III trial underway; IGA endpoint planned Gline said the LPP program has effectively begun as a “direct to registrational combined Phase IIb/III program,” with the study getting underway “last month.” He described a 72-patient Phase IIb portion that will transition immediately into a pivotal Phase III portion under a largely continuous design. The Phase III sample size is expected to be approximately 270 patients, with a sample size re-estimation after Phase IIb.

Management said the design is intended to support endpoint validation and regulatory alignment, while maintaining a pace closer to a straight-to-registrational program. Gline said the company is not yet providing enrollment timeline guidance but noted enthusiasm from investigators and patient communities.

On endpoints, Zimmer said Priovant is using a more structured approach than LPPAI. He described LPPAI as a composite measure with both physician-assessed and patient-reported components, but with limited definitions for raters. The company’s approach will include an investigator global assessment (IGA) focused on erythema and scale using defined criteria, with secondary endpoints to measure symptoms such as pain and itch using numerical rating scales.

In Q&A, Gline and Zimmer indicated the Phase IIb primary endpoint is expected to be an IGA 0/1 response with a two-point reduction, and said they expect—though cannot fully confirm until FDA discussions after Phase IIb—that the Phase III primary endpoint will match. Zimmer noted that placebo rates for rigorous IGA endpoints in inflammatory skin disorders tend to be low, particularly when requiring improvement to 0/1.

On background therapies, Gline said medications were washed out pre-baseline in the Mount Sinai investigator-initiated trial and highlighted that LPP patients often have polypharmacy. Zimmer said the registrational program plans to wash patients out of background medications “quite aggressively,” consistent with Priovant’s approach in other trials.

Batoclimab Phase III TED trial misses primary endpoint; Graves’ signals discussed Gline also addressed topline Phase III results in TED for batoclimab, Immunovant’s first-generation anti-FcRn antibody, stating the studies “failed to meet their primary endpoint.” He said the TED program was effectively the last readout for the first-generation molecule, with future development focused on IMVT-1402.

The TED primary endpoint was a ≥2 mm proptosis responder rate, which the trial did not achieve. Gline said the company is not pursuing further progress in TED with batoclimab, while noting the dataset provided scientific insights. He described the trial design as 12 weeks of high-dose batoclimab aimed at deep IgG suppression followed by 12 weeks of lower dosing. He said performance was generally better during the initial 12-week high-dose period than during the subsequent lower-dose period, a pattern he said was consistent across endpoints.

Gline said the trial showed “meaningful numerical separation” from placebo on change in proptosis at week 12, and noted that when pooling two TED studies, that measure was “nominally significant” in a post-hoc analysis, while emphasizing the limitations of such analyses. He added that proptosis improvements diminished between weeks 12 and 24 after dose reduction.

Management also highlighted results in a small subset of hyperthyroid patients included within TED enrollment criteria. Gline said there were about 20 hyperthyroid patients across active treatment arms in the pooled dataset. He reported a 75% mean IgG reduction and an 80% responder rate by a thyroid hormone definition (T3 and T4 below the upper limit of normal without increased antithyroid drug dosing), which he said matched the responder rate observed in a prior Phase II Graves’ study at week 12. He also said responder rates declined in the second 12-week period as IgG suppression lessened.

In response to analyst questions, Gline said hyperthyroid patients in the TED studies performed “somewhat better” on proptosis than the overall TED population. He also noted that antithyroid drug dose titration was not allowed in TED, limiting insight into real-world dose adjustments in that setting.

Gline said enrollment in the ongoing IMVT-1402 Graves’ program is “going well,” and reiterated expectations that both Graves’ studies will read out next year. He noted the Graves’ program excludes moderate to severe TED patients and is focused on endocrinology-driven sites, though the company expects to assess ocular symptom outcomes in Graves’ as well.

About Roivant Sciences (NASDAQ:ROIV) Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.

Featured Stories Five stocks we like better than Roivant Sciences

Investors might want to bet on Roivant Sciences Ltd. (ROIV - Free Report) , as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.

The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.

Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.

As such, the Zacks rating upgrade for Montes Archimedes Acquisition is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.

Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.

For Montes Archimedes Acquisition, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.

Harnessing the Power of Earnings Estimate RevisionsEmpirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .

Earnings Estimate Revisions for Montes Archimedes AcquisitionThis company is expected to earn -$1.07 per share for the fiscal year ending March 2026, which represents no year-over-year change.

Analysts have been steadily raising their estimates for Montes Archimedes Acquisition. Over the past three months, the Zacks Consensus Estimate for the company has increased 7.4%.

Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.

You can learn more about the Zacks Rank here >>>

The upgrade of Montes Archimedes Acquisition to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

Posted by Defense World Staff on Apr 15th, 2026

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $29.50.

ROIV has been the topic of a number of analyst reports. Weiss Ratings downgraded shares of Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, February 9th. HC Wainwright lifted their target price on shares of Roivant Sciences from $33.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Citigroup lifted their target price on shares of Roivant Sciences from $26.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, February 10th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Roivant Sciences in a research note on Tuesday, March 3rd. Finally, Sanford C. Bernstein began coverage on shares of Roivant Sciences in a research note on Friday, March 20th. They issued an “outperform” rating and a $35.00 price target on the stock.

View Our Latest Report on ROIV

Insiders Place Their Bets In other news, CAO Jennifer Humes sold 13,538 shares of the business’s stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $28.37, for a total value of $384,073.06. Following the sale, the chief accounting officer directly owned 84,191 shares of the company’s stock, valued at approximately $2,388,498.67. The trade was a 13.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Melissa B. Epperly sold 41,861 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $28.68, for a total transaction of $1,200,573.48. Following the completion of the sale, the director directly owned 15,804 shares in the company, valued at $453,258.72. This trade represents a 72.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 4,595,624 shares of company stock worth $124,848,136. Insiders own 10.80% of the company’s stock.

Institutional Investors Weigh In On Roivant Sciences A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Creek Drive Management Group LLC purchased a new stake in shares of Roivant Sciences in the 4th quarter valued at approximately $3,689,000. Hsbc Holdings PLC purchased a new stake in shares of Roivant Sciences in the 4th quarter valued at approximately $896,000. Pacer Advisors Inc. raised its stake in shares of Roivant Sciences by 24.0% in the 4th quarter. Pacer Advisors Inc. now owns 70,259 shares of the company’s stock valued at $1,525,000 after acquiring an additional 13,609 shares during the period. Dorsey Wright & Associates purchased a new stake in shares of Roivant Sciences in the 4th quarter valued at approximately $8,162,000. Finally, Invesco Ltd. raised its stake in shares of Roivant Sciences by 28.9% in the 4th quarter. Invesco Ltd. now owns 2,281,487 shares of the company’s stock valued at $49,508,000 after acquiring an additional 512,129 shares during the period. 64.76% of the stock is owned by hedge funds and other institutional investors.

Roivant Sciences Price Performance Shares of ROIV stock opened at $29.12 on Wednesday. The firm’s 50-day moving average is $27.68 and its two-hundred day moving average is $22.94. Roivant Sciences has a 12 month low of $9.90 and a 12 month high of $30.33. The company has a market capitalization of $20.84 billion, a PE ratio of -24.89 and a beta of 1.20.

About Roivant Sciences (Get Free Report)

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.

Further Reading Five stocks we like better than Roivant Sciences

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBrookfield Business (NYSE:BBUC) vs. Masonglory (NASDAQ:MSGY) Head-To-Head Survey

NEXT HEADLINE »Heartflow, Inc. (NASDAQ:HTFL) Given Average Rating of “Moderate Buy” by Analysts

DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update at 8:00 a.m.

Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript

BASEL, Switzerland and LONDON and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provided a business update.

Trump Index: 6 Companies Linked to Trump’s Cabinet Worth WatchingRoivant Sciences NASDAQ: ROIV executives used the company’s fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary hypertension data for mosliciguat and continued preparation for a potential brepocitinib launch in dermatomyositis.

Chief Executive Matt Gline called the company’s recent period “a pretty wild 12 months,” citing progress across development programs and the previously announced $2.25 billion settlement with Moderna. Gline said Roivant expects to receive the first $950 million upfront portion of that settlement in July.

Get Roivant Sciences alerts:

IMVT-1402 Shows Open-Label Activity in Refractory RA The most prominent update centered on preliminary data from the open-label portion of the 1402 study in difficult-to-treat rheumatoid arthritis, or D2T RA. Gline described the results as “surprisingly good,” while cautioning that the data came from an open-label phase of the trial.

The study enrolled heavily refractory patients who had failed steroids and DMARDs as well as at least two advanced lines of therapy. Gline said 65% of patients had failed JAK inhibitors, and that “basically every single one” of those patients had also failed a TNF inhibitor. The study also required autoantibody positivity using ACPA criteria.

In the preliminary period 1 data, Roivant reported that roughly 73% of evaluable patients achieved an ACR20 response. More than half achieved ACR50, and more than one-third achieved ACR70. Gline said the depth of response was especially notable because placebo responses are less common at the ACR50 and ACR70 levels.

“It feels to us like looking at this data, there’s something going on that’s meaningful and interesting with this drug,” Gline said.

Gline said the responses were “basically fully preserved” in the subset of patients who had prior JAK inhibitor exposure, a group he characterized as both JAK- and TNF-experienced. He said the findings support the biological thesis that ACPA positivity may represent a mechanism distinct from other anti-inflammatory approaches.

The randomized withdrawal portion of the study is still ongoing. Gline said more than half of patients remain on study treatment, and the company does not yet have data from period 2. He also noted that period 2 may be harder to interpret because patients with deep ACR50 or ACR70 responses may take time to lose an ACR20 response after withdrawal.

Roivant expects to share additional analysis, including patient-level data and feedback from discussions with the U.S. Food and Drug Administration, in the second half of the year. Gline said the company is preparing to discuss the data with regulators and hopes to outline next steps for the program.

Mosliciguat Data Expected in Second Half Roivant also provided a detailed preview of mosliciguat, an inhaled soluble guanylate cyclase, or sGC, activator being studied in pulmonary hypertension associated with interstitial lung disease, or PH-ILD. Drew Fromkin, CEO of Pulmovant, said mosliciguat is designed to activate sGC directly in the lungs and potentially address both pulmonary vascular disease and lung parenchymal disease.

Fromkin said Bayer previously studied mosliciguat in 170 participants, including healthy volunteers and pulmonary hypertension patients, before Roivant’s program advanced into PH-ILD. In phase I-B data, he said a single dose produced a mean pulmonary vascular resistance reduction of more than 30% and a mean peak reduction of about 38%. He also said the drug was well-tolerated, with mild to moderate treatment-emergent adverse events and no clinically meaningful systemic blood pressure or heart rate effects.

The ongoing PHocus phase II study enrolled 135 patients, above its target of 120. Fromkin said more than 95% of participants reached and sustained the 4-milligram dose through week 16. The primary endpoint is change from baseline in pulmonary vascular resistance at week 16, with secondary measures including six-minute walk distance and NT-proBNP.

Gline emphasized that the study is not powered to show a statistically significant benefit on six-minute walk distance. He said Roivant is primarily looking for confirmation of dosing, safety and pulmonary vascular resistance effects in the patient population.

Brepocitinib Launch Preparation Continues Roivant also updated investors on brepocitinib, which Gline said could potentially launch in dermatomyositis by the end of September if the FDA review proceeds as expected. He said the company is engaged in payer discussions, physician outreach, specialty pharmacy partnerships and unbranded patient engagement.

Gline said brepocitinib was awarded breakthrough therapy designation and rare therapy designation for cutaneous sarcoidosis. Roivant expects a phase III study in cutaneous sarcoidosis to begin this year. The company also recently announced lichen planopilaris, or LPP, as a fourth indication for brepocitinib, and Gline said that study is already enrolling.

For dermatomyositis, Gline described a high unmet need, noting that many patients rely on steroids, IVIG or off-label therapies. He said phase III brepocitinib data were published in the New England Journal of Medicine in March, which he called a testament to the importance and quality of the study.

Financial Position and Upcoming Milestones Gline said Roivant ended March 31 with $4.3 billion in cash and equivalents, before receipt of the Moderna settlement payment, and no debt. He also said the company continued to retire shares during the quarter.

Key milestones discussed on the call include:

Potential brepocitinib launch in dermatomyositis by the end of September, pending FDA action. Phase III top-line data in noninfectious uveitis expected in the second half of the year. Mosliciguat phase II-B top-line data in PH-ILD expected in the second half of 2026. Additional IMVT-1402 analysis in D2T RA, including FDA feedback, expected in the second half. IMVT-1402 data in Graves’ disease and myasthenia gravis expected in 2027. Gline said Roivant’s portfolio has “as much in the windshield as in the rearview mirror,” pointing to multiple data readouts and potential commercial activities ahead.

About Roivant Sciences NASDAQ: ROIVRoivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Roivant Sciences Right Now?Before you consider Roivant Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.

While Roivant Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbuster assets, notably through Immunovant's IMVT-1402 in rheumatoid arthritis. IMVT-1402 delivered strong Phase 2 efficacy in difficult-to-treat rheumatoid arthritis, with ACR20/50/70 rates of 72.7%, 54.5%, and 35.8%, respectively. ROIV's financial position is robust, ending the quarter with $4.3 billion in cash and a management-asserted runway to profitability.

Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript